Immune-Related Adverse Events, Specifically Pneumonitis, with the Use of Programmed Death-1 Inhibitors

被引：0
|
作者：
Chang, W. J. [1 ]
Dowlati, A. [2 ]
Teba, C. V. [1 ]
Kazakov, J. [3 ]
机构：
[1] Case Western Reserve Univ, Div Pulm Crit Care & Sleep Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Div Hematol & Oncol, Cleveland, OH 44106 USA
[3] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4530
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Immune-Related Adverse Events: Pneumonitis
    Jain, Akash
    Shannon, Vickie R.
    Sheshadri, Ajay
    [J]. IMMUNOTHERAPY, 2ND EDITION, 2018, 995 : 131 - 149
  • [2] Immune-Related Adverse Events: Pneumonitis
    Zhong, Linda
    Altan, Mehmet
    Shannon, Vickie R.
    Sheshadri, Ajay
    [J]. IMMUNOTHERAPY, 3RD EDITION, 2020, 1244 : 255 - 269
  • [3] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [4] Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
    Hou, Yong-Zhe
    Zhang, Qin
    Bai, Hai
    Wu, Tao
    Chen, Ya-Jie
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (07) : 1458 - 1466
  • [5] Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
    Yong-Zhe Hou
    Qin Zhang
    Hai Bai
    Tao Wu
    Ya-Jie Chen
    [J]. World Journal of Clinical Cases, 2023, (07) : 1458 - 1466
  • [6] Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
    Judd, Julia
    Zibelman, Matthew
    Handorf, Elizabeth
    O'Neill, John
    Ramamurthy, Chethan
    Bentota, Sasini
    Doyle, Jamie
    Uzzo, Robert G.
    Bauman, Jessica
    Borghaei, Hossein
    Plimack, Elizabeth R.
    Mehra, Ranee
    Geynisman, Daniel M.
    [J]. ONCOLOGIST, 2017, 22 (10): : 1232 - 1237
  • [7] Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication
    Aya, Francisco
    Gonzalez-Navarro, E. Azucena
    Martinez, Clara
    Carcelero, Esther
    Arance, Ana
    [J]. IMMUNOTHERAPY, 2021, 13 (09) : 745 - 752
  • [8] Real-World Evidence of the Incidence of and Risk Factors for Type 1 Diabetes Mellitus and Hypothyroidism as Immune-Related Adverse Events Associated With Programmed Cell Death-1 Inhibitors
    Shimada, Koki
    Yamamoto, Hiroyuki
    Nakatani, Eiji
    Kumamaru, Hiraku
    Nishimura, Shiori
    Ichihara, Nao
    Hirahara, Norimichi
    Mori, Kiyoshi
    Kotani, Masato
    Miyachi, Yoshiki
    Miyata, Hiroaki
    [J]. ENDOCRINE PRACTICE, 2021, 27 (06) : 586 - 593
  • [9] Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Ramos-Casals, Manuel
    Siso-Almirall, Antoni
    [J]. ANNALS OF INTERNAL MEDICINE, 2024, : ITC17 - ITC32
  • [10] Immune-related adverse events of checkpoint inhibitors
    Ramos-Casals, Manuel
    Brahmer, Julie R.
    Callahan, Margaret K.
    Flores-Chavez, Alejandro
    Keegan, Niamh
    Khamashta, Munther A.
    Lambotte, Olivier
    Marlette, Xavier
    Prat, Aleix
    Suarez-Almazor, Maria E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)
12345